Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Nokia reported for 6 months of 2023

7/20/23 NOK

Alcoa reported for 6 months of 2023

7/20/23 AA

IBM reported for 6 months of 2023

7/20/23 IBM

Tesla has reported for Q2 2023

7/20/23 TSLA

Netflix reported for 6 months of 2023

7/20/23 NFLX

Sberbank may open a branch in Bangladesh

7/20/23 SBER

Trading in Polymetal shares suspended for redomiciliation

7/20/23 POLY

Activision Blizzard has reported for 6 months of 2023

7/19/23 ATVI

TMK's holding structure redomiciled to Russky Island

7/19/23 TRMK

Goldman Sachs reported for 6 months of 2023

7/19/23 GS